Literature DB >> 11866646

Evaluation of investigations conducted to detect and prevent transmission of tuberculosis.

Mary R Reichler1, Randall Reves, Sarah Bur, Virginia Thompson, Bonita T Mangura, Josie Ford, Sarah E Valway, Ida M Onorato.   

Abstract

CONTEXT: Contact investigations are routinely conducted by health departments throughout the United States for all cases of active pulmonary tuberculosis (TB) to identify secondary cases of active TB and latent TB infection and to initiate therapy as needed in these contacts. Little is known about the actual procedures followed, or the results.
OBJECTIVES: To evaluate contact investigations conducted by US health departments and the outcomes of these investigations. DESIGN, SETTING, AND
SUBJECTS: Review of health department records for all contacts of 349 patients with culture-positive pulmonary TB aged 15 years or older reported from 5 study areas in the United States during 1996. MAIN OUTCOME MEASURES: Number of contacts identified, fully screened, and infected per TB patient; rates of TB infection and disease among contacts of TB patients; and type and completeness of data collected during contact investigations.
RESULTS: A total of 3824 contacts were identified for 349 patients with active pulmonary TB. Of the TB patients, 45 (13%) had no contacts identified. Of the contacts, 55% completed screening, 27% had an initial but no postexposure tuberculin skin test, 12% were not screened, and 6% had a history of prior TB or prior positive tuberculin skin test. Of 2095 contacts who completed screening, 68% had negative skin test results, 24% had initial positive results with no prior test result available, 7% had documented skin test conversions, and 1% had active TB at the time of investigation. Close contacts younger than 15 years (76% screened vs 65% for older age groups; P<.001) or exposed to a TB patient with a positive smear (74% screened vs 59% for those with a negative smear; P<.001) were more likely to be fully screened. Close contacts exposed to TB patients with both a positive smear and a cavitary chest radiograph were more likely to have TB infection or disease (62% vs 33% for positive smear only vs 44% for cavitary radiograph only vs 37% for neither characteristic; P<.001). A number of factors associated with TB patient infectiousness, contact susceptibility to infection, contact risk of progression to active TB, and amount of contact exposure to the TB patient were not routinely recorded in health department records.
CONCLUSIONS: Improvement is needed in the complex, multistep process of contact investigations to ensure that contacts of patients with active pulmonary TB are identified and appropriately screened.

Entities:  

Mesh:

Year:  2002        PMID: 11866646     DOI: 10.1001/jama.287.8.991

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  59 in total

1.  Standardizing contact investigation protocols.

Authors:  L B Gerald; F Bruce; C M Brooks; N Brook; M E Kimerling; R A Windsor; W C Bailey
Journal:  Int J Tuberc Lung Dis       Date:  2003-12       Impact factor: 2.373

2.  Transmission network analysis to complement routine tuberculosis contact investigations.

Authors:  McKenzie Andre; Kashef Ijaz; Jon D Tillinghast; Valdis E Krebs; Lois A Diem; Beverly Metchock; Theresa Crisp; Peter D McElroy
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

3.  The implications of immunopathology for parasite evolution.

Authors:  Alex Best; Gráinne Long; Andy White; Mike Boots
Journal:  Proc Biol Sci       Date:  2012-05-02       Impact factor: 5.349

4.  Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Authors:  D Shepardson; S M Marks; H Chesson; A Kerrigan; D P Holland; N Scott; X Tian; A S Borisov; N Shang; C M Heilig; T R Sterling; M E Villarino; W R Mac Kenzie
Journal:  Int J Tuberc Lung Dis       Date:  2013-12       Impact factor: 2.373

5.  Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda.

Authors:  Emmanuel Ssemmondo; Florence Mwangwa; Joel L Kironde; Dalsone Kwarisiima; Tamara D Clark; Carina Marquez; Edwin D Charlebois; Maya L Petersen; Moses R Kamya; Diane V Havlir; Gabriel Chamie
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

6.  Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis.

Authors:  Mary R Reichler; Awal Khan; Timothy R Sterling; Hui Zhao; Bin Chen; Yan Yuan; Joyce Moran; James McAuley; Bonita Mangura
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

7.  Tuberculosis incidence among contacts of active pulmonary tuberculosis.

Authors:  M Cailleaux-Cezar; D de A Melo; G M Xavier; C L G de Salles; F C Q de Mello; A Ruffino-Netto; J E Golub; A Efron; R E Chaisson; M B Conde
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

8.  Risk factors for transmission of tuberculosis among United States-born African Americans and Whites.

Authors:  M A Pagaoa; R A Royce; M P Chen; J E Golub; A L Davidow; Y Hirsch-Moverman; S M Marks; L D Teeter; P M Thickstun; D J Katz
Journal:  Int J Tuberc Lung Dis       Date:  2015-12       Impact factor: 2.373

9.  DNA fingerprinting of Mycobacterium tuberculosis isolates from epidemiologically linked case pairs.

Authors:  Diane E Bennett; Ida M Onorato; Barbara A Ellis; Jack T Crawford; Barbara Schable; Robert Byers; J Steve Kammerer; Christopher R Braden
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

10.  The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts.

Authors:  Chuan-Chin Huang; Eric Tchetgen Tchetgen; Mercedes C Becerra; Ted Cohen; Katherine C Hughes; Zibiao Zhang; Roger Calderon; Rosa Yataco; Carmen Contreras; Jerome Galea; Leonid Lecca; Megan Murray
Journal:  Clin Infect Dis       Date:  2013-12-23       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.